Company: ATRA
Filing Date: 2025-10-07
Form Type: 8-K
Source: 0001193125-25-232117
Chunk: 0

Company: Atara Biotherapeutics, Inc.
Filing Date: 2025-10-07
Form: 8-K
Item: Item 2.05
Chunk 0
---
Item 2.05      Costs Associated with Exit or Disposal Activities.  

On October 6, 2025, Atara Biotherapeutics, Inc. (the “ Company”) announced a reduction in its workforce that will impact approximately 29% of its current employees, retaining approximately 15 employees essential to executing on the Company’s strategic priorities. The Company expects to complete the workforce reduction by January 2026. The Company expects to recognize approximately $1.3 million for severance and related benefits for employees laid off under the reduction in force. Approximately fifty percent of these charges are salary continuation payments and wages for the60-daynotice period in accordance with the California Worker Adjustment and Retraining Notification Act. The Company may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the workforce reduction. Additional details will be provided in the Company’s Quarterly Report on Form10-Qfor the period ending September 30, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                                      ATARA BIOTHERAPEUTICS, INC.                                
  Date: October 6, 2025      By:      /s/ AnhCo Thieu Nguyen                                     
                                      AnhCo Thieu Nguyen